Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma. (31st August 2021)

• Record Type: Journal Article
• Authors: Jiang, Junjie; Wang, Hui-Ju; Mou, Xiao-Zhou; Zhang, Huanqing; Chen, YiZhen; Hu, Zhi-Ming
• Is Part Of: Technology in cancer research & treatment. Volume 20(2021)
• Publication Date: 2021-08-31
• Subjects: KAT6B -- MYST -- ING5 -- immunohistochemistry -- hepatocellular carcinoma; Oncology -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Technological innovations -- Periodicals; 616.994
• DOI: 10.1177/15330338211033063
• Languages: English
• ISSNs: 1533-0346

Abstract

Aims: Lysine acetyltransferase 6B (KAT6B), is a histone acetyltransferase implicated to have a role in tumor suppression. However, the relationship between KAT6B and hepatocellular carcinoma (HCC) is unclear. The purpose of this study was to detect the expression of KAT6B in HCC tissues and analyze its connection with the clinicopathological features of HCC. Methods: First, we performed immunohistochemical staining on 250 HCC tissues and 222 non-tumor liver tissues to examine the expression of KAT6B.Then the relation between KAT6B expression and clinicopathological parameters was analyzed by chi-square test, and the overall survival analysis was conducted by Kaplan-Meier survival method. In addition, based on the Oncomine expression array online and the UALCAN database, we compared KAT6B expression differences between normal liver tissues and HCC tissues more broadly. Results: Compared with normal tissues, KAT6B expression was significantly lower in HCC tissues. Low KAT6B expression was found to be related to gender, AFP level, and tumor size. According to the online database, KAT6B expression was found to be decreased in HCC tissues and high in normal tissues. Conclusions: Lower expression of KAT6B is associated with poor prognosis of HCC, and KAT6B may be a potential tumor suppressor in liver cancer.